Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Berenberg hikes target price on Currys

(Sharecast News) - Analysts at Berenberg hiked their target price on retailer Currys from 125.0p to 175.0p on Friday following the group's latest guidance upgrade. Berenberg said Currys' upgrade reaffirmed its view of the group as "a top pick for 2025" and raised its FY25 group adjusted pre-tax profits by roughly 6% to £160.0m, which flows through to outer years.

The German bank, which reiterated its 'buy' rating on the stock, said this means that following the raft of previous upgrades, it has now raised its FY25 profit forecast by a cumulative 30% over the past 12 months.

"This makes Currys a standout performer in the UK consumer sector, particularly when set against: i) other companies that have downgraded their guidance; ii) the ongoing inflationary cost environment; and iii) the emerging tariff war, which should have little impact on Currys," said Berenberg.

"Our raised forecasts and the group's increasingly optimistic outlook drive our DCF-based price target up to 175.0p, which should still prove prudent."

Reporting by Iain Gilbert at Sharecast.com

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.